Viking Therapeutics 주식 (NASDAQ: VKTX)

에 대한 최신 뉴스 Viking Therapeutics (NASDAQ:VKTX) 주식

Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Biotech

Technicals

Trading Ideas

General

VKTX

바이킹 테라퓨틱스(NASDAQ:VKTX)의 주가가 금요일 개장 전 잠재적인 데스 크로스 바로 위에서 맴돌고 있어 중요한 순간을 맞이하고 있다. 50일 이동평균선이 200일 이동평균선 아래로 떨어지는 이 불길한 기술적 패턴은 종종 약세 신호로 간주된다. 아직 확정되지는 않았지만, 주식의 궤적은 최근 몇 달 동안 이전의 상승에도 불구하고 주가에 대한 압박이 증가하고 있음을 시사한다.

바이킹 테라퓨틱스 주식, 체중 감량 흥분이 둔화되며 데스 크로스 형성 직전

Mid Cap

News

Movers

ASTS

BEAM

CLDX

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

PEGA

PTGX

VSAT

다음은 지난주 큰 폭의 상승세를 보인 6개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? AST 스페이스모바일(NASDAQ:ASTS)의 주가는 회사가 첫 5개의 상용 위성을 성공적으로 완료하면서 47.88% 상승했다.

비아샛 및 AST 스페이스모바일은 지난주 최고 성과를 보여준 6개 중형주 중 일부 (7월 21일-7월 27일)

Equities

Markets

NVDA

TSLA

수요일 미국 주요 지수는 크게 하락세로 마감했다. 다우존스 산업평균지수는 1.25% 하락한 39,853.87에, S&amp;P 500 지수는 2.3% 하락한 5,427.13에, 나스닥 지수는 3.6% 하락한 17,342.41에 마감했다. 이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:

수요일 주목받은 주식 5종목: 엔비디아, 포드, 치폴레, 바이킹 테라퓨틱스, 테슬라

Viking Therapeutics Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)</h3>
<ul>
<li>On Jan. 17, HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated Viking Therapeutics with a Buy and maintained a $102 price target.. The company' stock fell around 22% over the past month and has a <a href="https://www.benzinga.com/quote/VKTX">52-week low of $20.83</a>.</li>
<li>RSI Value: 28.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VKTX Price Action: Shares of Viking Therapeutics gained 0.7% to close at $32.87 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">latest VKTX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png" alt="" class="wp-image-744179" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-768x707.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Radnet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Jan. 15, Jefferies analyst Brian Tanquilut maintained RadNet with a Buy rating and lowered the price target from $100 to $80. The company's stock fell around 11% over the past five days and <a href="https://www.benzinga.com/quote/RDNT">has a 52-week low</a> of $35.16.</li>
<li>RSI Value: 25.2</li>
<li>RDNT Price Action: Shares of Radnet gained 0.6% to close at $60.19 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">trend in RDNT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png" alt="" class="wp-image-744183" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-768x704.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)</h3>
<ul>
<li>On Jan. 13, Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera's position in B cell modulation. The company's stock fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VERA">low of $15.46.</a></li>
<li>RSI Value: 27.2</li>
<li>VERA Price Action: Shares of Vera Therapeutics gained 1% to close at $33.70 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">VERA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png" alt="" class="wp-image-744188" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-768x719.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

Pre-Market Outlook

RDNT

VERA

Top 3 Health Care Stocks That Could Blast Off This Quarter

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $102 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) has outperformed the market over the past 5 years by 23.35% on an annualized basis producing an average annual return of 35.65%. Currently, Viking Therapeutics has a market capitalization of $3.63 billion. 
Buying $1000 In VKTX: If an investor had bought $1000 of VKTX stock 5 years ago, it would be worth $4,592.38 today based on a price of $32.60 for VKTX at the time of writing.
<h3>Viking Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737066616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $102 price target.

HC Wainwright & Co. Maintains Buy on Viking Therapeutics, Maintains $102 Price Target

VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics Initiates Phase 2 Clinical Trial Of The Oral Tablet Formulation Of VK2735

JPMorgan has reset the valuation for Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) and Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>).
Analyst Hardik Parikh cites several reasons for recovery, including pathways for strategic partnership with pharma, some clinical trial data points and additional clarity on the incoming administration&#8217;s policies on GLP-1 access.
The analyst writes that <a target="_blank" href="https://www.benzinga.com/quote/VKTX" rel="noreferrer noopener">Viking Therapeutics</a> and <a target="_blank" href="https://www.benzinga.com/quote/GPCR" rel="noreferrer noopener">Structure Therapeutics</a> are attractive pure-play options for investing in the T2D/obesity market opportunity overall.
The note continues, saying that Viking Therapeutics and Structure Therapeutics remain attractive partners for pharmaceutical companies looking to enter the T2D/obesity market relatively quickly.
It expects a reasonable case to make that many pharmaceutical companies, in addition to Merck &amp; Co. Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), could be active in the space. Hence, Viking Therapeutics and Structure Therapeutics still have abundant pathways <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42560386/whats-going-on-with-viking-therapeutics-stock-on-wednesday" rel="noreferrer noopener">to strategic partnerships</a>.
Viking Therapeutics and Structure Therapeutics can help address growth gaps for pharma over time, analyst Parikh says, and sees an apparent disconnect on valuation abates over time.
The analyst sees the competitive bar for VK2735 primarily unchanged, at least in the near term, after Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) phase 3 Redefine-1 data showed weight loss from cagriSema that is on par with Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound.
The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">injectables in development</a>.
Viking Therapeutics highlighted new clinical data from its VK2735 obesity program in two poster presentations&nbsp;at ObesityWeek&nbsp;2024.
Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">ranging up to 8.2%</a>.
JPMorgan suggests that VK2735&#8217;s weight-loss effectiveness in its upcoming Phase 3 trial (starting in early 2025) could slightly surpass Zepbound&#8217;s ~22% reduction at 72 weeks and remain competitive with CagriSema.
However, the firm believes Eli Lilly&#8217;s retatrutide may set the highest standard for efficacy, potentially achieving weight loss in the high 20% range, based on Phase 3 data expected in 2026. While this creates a challenging benchmark for VK2735, its tolerability could offer an edge over retatrutide, which is expected to have slightly more side effects than Zepbound.
Last month, Structure Therapeutics selected ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity and related diseases. The compound is expected to be in Phase 1 clinical development by the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42539839/structure-therapeutics-announces-selection-of-lead-oral-small-molecule-amylin-receptor-agonist-acc" rel="noreferrer noopener">end of 2025</a>.
In November, Structure Therapeutics dosed the first patient in Phase 2b ACCESS trial of GSBR-1290 obese or overweight patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41953633/structure-therapeutics-announces-first-patients-dosed-in-phase-2b-access-clinical-study-evaluating" rel="noreferrer noopener">weight-related comorbidity</a>.
VKTX, GCPR Price Actions: Viking Therapeutics stock is down 0.56% at $42.65, and Structure Therapeutics stock is down 0.25% at $27.51 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/42819611/cvs-health-aetna-files-lawsuit-against-drugmakers-for-alleged-inflated-generic-drug-prices" target="_blank" rel="noreferrer noopener">CVS Health&#8217;s Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

Analyst Color

Health Care

GPCR

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) has outperformed the market over the past 5 years by 26.16% on an annualized basis producing an average annual return of 38.91%. Currently, Viking Therapeutics has a market capitalization of $4.45 billion. 
Buying $1000 In VKTX: If an investor had bought $1000 of VKTX stock 5 years ago, it would be worth $5,055.35 today based on a price of $39.95 for VKTX at the time of writing.
<h3>Viking Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735569910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years

Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 40% bearish. Among these notable options, 4 are puts, totaling $243,720, and 6 are calls, amounting to $226,072.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $50.0 for Viking Therapeutics over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Viking Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Viking Therapeutics's substantial trades, within a strike price spectrum from $30.0 to $50.0 over the preceding 30 days.
<h3>Viking Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735231532_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.5</td>
<td>$10.3</td>
<td>$10.4</td>
<td>$50.00</td>
<td>$126.8K</td>
<td>1.0K</td>
<td align="right">184</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.7</td>
<td>$7.3</td>
<td>$7.37</td>
<td>$50.00</td>
<td>$65.8K</td>
<td>2.0K</td>
<td align="right">97</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$44.50</td>
<td>$46.7K</td>
<td>3</td>
<td align="right">117</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.6</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$50.00</td>
<td>$41.6K</td>
<td>1.0K</td>
<td align="right">62</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.76</td>
<td>$50.00</td>
<td>$37.6K</td>
<td>3.8K</td>
<td align="right">402</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Having examined the options trading patterns of Viking Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Viking Therapeutics</h3>
<ul>
<li>With a trading volume of 694,938, the price of VKTX is down by -0.83%, reaching $42.0.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $95.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $74. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Unpacking the Latest Options Trading Trends in Viking Therapeutics

Viking Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NYSE">VKTX</a>) short percent of float has risen 6.35% since its last report. The company recently reported that it has 18.07 million shares sold short, which is 21.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Viking Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Viking Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Viking Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Viking Therapeutics's peer group average for short interest as a percentage of float is 13.65%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Viking Therapeutics's Recent Short Interest

On Wednesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42549621/merck-enters-into-exclusive-global-license-agreement-with-hansoh-pharma-for-investigational-oral-g" rel="noreferrer noopener">molecule GLP-1 receptor agonist</a>.
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the candidate&#8217;s development, regulatory approval, and commercialization, as well as royalties on sales.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42096338/viking-therapeutics-garners-analyst-support-for-nash-and-metabolic-programs" rel="noreferrer noopener">Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs</a>
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
William Blair writes that Merck is seen as a strong candidate to acquire Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), leading to an expected sell-off in Viking shares. However, the analyst notes that the licensing agreement with Hansoh will not hinder Merck from pursuing additional external business development opportunities in the obesity space.
The licensing deal highlights Merck&#8217;s commitment to obesity, potentially driving further growth through additional partnerships. While the focus on Viking increases investment volatility, data from competitors or new licensing deals could significantly affect its stock.
William Blair remains confident that Viking offers a valuable asset with VK2735, a GLP-1/GIP dual agonist that could become a major player in obesity treatment due to its potential for monthly maintenance <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">dosing and oral formulation options</a>.
This asset could strengthen an acquiring company&#8217;s obesity portfolio, with additional potential from Viking&#8217;s amylin program.
Overall, the analyst is optimistic about Viking&#8217;s prospects, maintaining the stock as a top pick for 2025 and an Outperform <a target="_blank" href="https://www.benzinga.com/quote/VKTX/analyst-ratings" rel="noreferrer noopener">rating on its shares</a>.
Price Action: VKTX stock is down 11.4% at $41.37 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42559199/renewable-energy-company-orsted-sells-50-stake-in-us-solar-and-battery-projects-for-572m" target="_blank" rel="noreferrer noopener">Renewable Energy Company Ørsted Sells 50% Stake In US Solar And Battery Projects For $572 Million: Details</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Contracts

What's Going On With Viking Therapeutics Stock On Wednesday?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRDF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$56.3K</td>
<td>1.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$500.00</td>
<td>$51.9K</td>
<td>2.4K</td>
<td>687</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$32.00</td>
<td>$34.4K</td>
<td>2.0K</td>
<td>648</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$37.00</td>
<td>$47.5K</td>
<td>1.8K</td>
<td>321</td>
</tr>
<tr>
<td>PEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$280.00</td>
<td>$52.2K</td>
<td>0</td>
<td>223</td>
</tr>
<tr>
<td>NMRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$36.0K</td>
<td>13.7K</td>
<td>104</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$90.00</td>
<td>$25.0K</td>
<td>3.6K</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$97.00</td>
<td>$25.8K</td>
<td>28</td>
<td>46</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$290.00</td>
<td>$29.8K</td>
<td>26</td>
<td>42</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$780.00</td>
<td>$127.8K</td>
<td>238</td>
<td>27</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding CRDF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>), we observe a call option sweep with bullish sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 663 contract(s) at a $5.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $56.3K, with a price of $88.0 per contract. There were 1040 open contracts at this strike prior to today, and today 1104 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option sweep that happens to be neutral, expiring in 30 day(s) on January 17, 2025. This event was a transfer of 21 contract(s) at a $500.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $51.9K, with a price of $2480.0 per contract. There were 2415 open contracts at this strike prior to today, and today 687 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on December 20, 2024. This event was a transfer of 128 contract(s) at a $32.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $34.4K, with a price of $279.0 per contract. There were 2000 open contracts at this strike prior to today, and today 648 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option sweep with bullish sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $37.00 strike. This particular put needed to be split into 41 different trades to become filled. The total cost received by the writing party (or parties) was $47.5K, with a price of $190.0 per contract. There were 1897 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• For PEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), we notice a call option trade that happens to be bullish, expiring in 212 day(s) on July 18, 2025. This event was a transfer of 25 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $52.2K, with a price of $2090.0 per contract. There were 0 open contracts at this strike prior to today, and today 223 contract(s) were bought and sold. 
• Regarding NMRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>), we observe a call option trade with neutral sentiment. It expires in 30 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $360.0 per contract. There were 13769 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option trade with bullish sentiment. It expires in 394 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 3611 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bearish sentiment. It expires in 2 day(s) on December 20, 2024. Parties traded 22 contract(s) at a $97.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $1175.0 per contract. There were 28 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option sweep that happens to be neutral, expiring in 120 day(s) on April 17, 2025. This event was a transfer of 15 contract(s) at a $290.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $29.8K, with a price of $1990.0 per contract. There were 26 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be neutral, expiring in 184 day(s) on June 20, 2025. This event was a transfer of 18 contract(s) at a $780.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $127.8K, with a price of $7105.0 per contract. There were 238 open contracts at this strike prior to today, and today 27 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRDF

NMRA

10 Health Care Stocks With Whale Alerts In Today's Session

Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 77% bearish. Among these notable options, 2 are puts, totaling $53,630, and 7 are calls, amounting to $255,390.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $65.0 for Viking Therapeutics, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Viking Therapeutics stands at 1159.25, with a total volume reaching 3,361.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $45.0 to $65.0, throughout the last 30 days.
<h3>Viking Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734536723_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.4</td>
<td>$5.1</td>
<td>$5.2</td>
<td>$60.00</td>
<td>$52.0K</td>
<td align="right">829</td>
<td align="right">273</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$60.00</td>
<td>$52.0K</td>
<td align="right">829</td>
<td align="right">173</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$45.00</td>
<td>$35.6K</td>
<td align="right">271</td>
<td align="right">280</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$45.00</td>
<td>$33.6K</td>
<td align="right">271</td>
<td align="right">822</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$45.00</td>
<td>$31.0K</td>
<td align="right">271</td>
<td align="right">578</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
After a thorough review of the options trading surrounding Viking Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Viking Therapeutics</h3>
<ul>
<li>With a trading volume of 3,362,736, the price of VKTX is down by -9.27%, reaching $42.37.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 49 days from now.</li>
</ul>
<h3>Expert Opinions on Viking Therapeutics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $97.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $74. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $102. 
&#x2A; Reflecting concerns, an analyst from B. Riley Securities lowers its rating to Buy with a new price target of $109. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $102. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Smart Money Is Betting Big In VKTX Options

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$17.00</td>
<td>$167.5K</td>
<td>17.1K</td>
<td>2.9K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$500.00</td>
<td>$29.9K</td>
<td>1.3K</td>
<td>2.2K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$54.7K</td>
<td>6.6K</td>
<td>1.8K</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$180.00</td>
<td>$292.5K</td>
<td>6.2K</td>
<td>1.6K</td>
</tr>
<tr>
<td>VRDN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$22.50</td>
<td>$27.0K</td>
<td>458</td>
<td>599</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$580.00</td>
<td>$57.1K</td>
<td>475</td>
<td>250</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$80.00</td>
<td>$45.0K</td>
<td>14</td>
<td>99</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$40.00</td>
<td>$32.6K</td>
<td>615</td>
<td>25</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$25.00</td>
<td>$25.1K</td>
<td>42</td>
<td>12</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 2500 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $167.5K, with a price of $67.0 per contract. There were 17104 open contracts at this strike prior to today, and today 2970 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 38 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $29.9K, with a price of $788.0 per contract. There were 1381 open contracts at this strike prior to today, and today 2262 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 205 contract(s) at a $50.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $54.7K, with a price of $267.0 per contract. There were 6605 open contracts at this strike prior to today, and today 1828 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bearish, expiring in 760 day(s) on January 15, 2027. This event was a transfer of 25 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $292.5K, with a price of $11700.0 per contract. There were 6297 open contracts at this strike prior to today, and today 1688 contract(s) were bought and sold. 
• For VRDN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), we notice a call option trade that happens to be bearish, expiring in 4 day(s) on December 20, 2024. This event was a transfer of 200 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $27.0K, with a price of $135.0 per contract. There were 458 open contracts at this strike prior to today, and today 599 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a put option sweep with bearish sentiment. It expires in 4 day(s) on December 20, 2024. Parties traded 56 contract(s) at a $580.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $1020.0 per contract. There were 475 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a call option trade with bullish sentiment. It expires in 32 day(s) on January 17, 2025. Parties traded 98 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $460.0 per contract. There were 14 open contracts at this strike prior to today, and today 99 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option trade with neutral sentiment. It expires in 95 day(s) on March 21, 2025. Parties traded 20 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $32.6K, with a price of $1630.0 per contract. There were 615 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be neutral, expiring in 151 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $25.1K, with a price of $2517.0 per contract. There were 42 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PRAX

TEVA

VRDN

9 Health Care Stocks With Whale Alerts In Today's Session

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) has outperformed the market over the past 5 years by 30.12% on an annualized basis producing an average annual return of 43.71%. Currently, Viking Therapeutics has a market capitalization of $5.24 billion. 
Buying $100 In VKTX: If an investor had bought $100 of VKTX stock 5 years ago, it would be worth $596.07 today based on a price of $47.00 for VKTX at the time of writing.
<h3>Viking Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<a href="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic" title="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic">https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic</a>

AMGN

DRIO

LFVN

TERN

VANI

"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XRAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$40.5K</td>
<td>3.2K</td>
<td>2.1K</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$30.0K</td>
<td>8.4K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$50.00</td>
<td>$86.8K</td>
<td>9.6K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LFST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.00</td>
<td>$35.0K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$42.00</td>
<td>$33.0K</td>
<td>536</td>
<td>281</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$95.00</td>
<td>$44.7K</td>
<td>439</td>
<td>161</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$145.00</td>
<td>$26.1K</td>
<td>2.0K</td>
<td>95</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$470.00</td>
<td>$33.2K</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$65.00</td>
<td>$29.1K</td>
<td>278</td>
<td>11</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$470.00</td>
<td>$29.0K</td>
<td>1</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For XRAY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), we notice a call option trade that happens to be neutral, expiring in 128 day(s) on April 17, 2025. This event was a transfer of 225 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $40.5K, with a price of $180.0 per contract. There were 3202 open contracts at this strike prior to today, and today 2122 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 400 contract(s) at a $9.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $75.0 per contract. There were 8401 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 482 contract(s) at a $50.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $86.8K, with a price of $180.0 per contract. There were 9650 open contracts at this strike prior to today, and today 1214 contract(s) were bought and sold. 
• Regarding LFST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $70.0 per contract. There were 1847 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on January 17, 2025. This event was a transfer of 314 contract(s) at a $42.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $33.0K, with a price of $105.0 per contract. There were 536 open contracts at this strike prior to today, and today 281 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 101 day(s) on March 21, 2025. This event was a transfer of 50 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $44.7K, with a price of $895.0 per contract. There were 439 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 67 contract(s) at a $145.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $26.1K, with a price of $390.0 per contract. There were 2061 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a call option trade that happens to be neutral, expiring in 283 day(s) on September 19, 2025. This event was a transfer of 20 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $1660.0 per contract. There were 22 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be neutral, expiring in 402 day(s) on January 16, 2026. This event was a transfer of 11 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.1K, with a price of $2654.0 per contract. There were 278 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on January 24, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $2900.0 per contract. There were 1 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

LFST

RXRX

VRTX

XRAY

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) revealed 9 unusual trades.
Delving into the details, we found 66% of traders were bullish, while 22% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $176,679, and 4 were calls, valued at $135,200.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $45.0 to $70.0 for Viking Therapeutics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 844.0 with a total volume of 917.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $45.0 to $70.0 over the last 30 days.
<h3>Viking Therapeutics Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733417246_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.5</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$45.00</td>
<td>$49.5K</td>
<td>371</td>
<td align="right">121</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$17.3</td>
<td>$16.8</td>
<td>$17.13</td>
<td>$65.00</td>
<td>$41.4K</td>
<td>331</td>
<td align="right">30</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$67.50</td>
<td>$39.6K</td>
<td>91</td>
<td align="right">30</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$70.00</td>
<td>$32.0K</td>
<td>3.0K</td>
<td align="right">151</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.19</td>
<td>$70.00</td>
<td>$31.9K</td>
<td>3.0K</td>
<td align="right">251</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Viking Therapeutics Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 623,928, the VKTX's price is up by 1.21%, now at $51.86. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $96.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
&#x2A; An analyst from B. Riley Securities downgraded its action to Buy with a price target of $109. 
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $74. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy. Annabel Samimy's rating is based on...

Positive Buy Rating on Viking Therapeutics Driven by Promising VK2735 Program Advances

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today. Hardik Parikh has given his Buy rat...

Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price t...

Positive Outlook for Viking Therapeutics Amid Promising Trial Developments

JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it has initiated the ph2a t...

Viking Therapeutics' oral-2735 could differentiate asset, says JPMorgan

Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?

3 Oversold Biotech Names

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9. Joseph Pantginis has ...

Viking Therapeutics' VK2735: A Promising Contender in the Weight-Loss Market with Superior Efficacy Profile

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss over ...

Novo Nordisk data boosts H.C. Wainwright confidence in Viking's potential

BUZZ Investing: Markets React To Fed Rate Cut As Renewed Inflation Risks Emerge

Viking Therapeutics: The Turning Point Is Not Here Yet

AVDL

AVGO

BIIB

BUZZ

CELH

CHWY

COIN

CRSP

CVNA

FOLD

GILD

HOOD

JAZZ

LCID

MDGL

MRNA

NONOF

NVCR

PLTR

QURE

REGN

RKLB

SAGE

SMCI

SMMT

SOFI

SOUN

SRPT

SRRK

UBER

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Small Cap

Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Alkermes

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Grifols, S.A. - American Depositary Shares

Grifols

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Kymera Therapeutics

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

TG Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

Piper Sandler

B. Riley Securities

Oppenheimer

Morgan Stanley

바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)의 주가가 금요일 개장 전 <a href="https://kr.benzinga.com/?s=%EB%8D%B0%EC%8A%A4+%ED%81%AC%EB%A1%9C%EC%8A%A4++" target="_blank" rel="noopener">잠재적인 데스 크로스</a> 바로 위에서 맴돌고 있어 중요한 순간을 맞이하고 있다.
50일 이동평균선이 200일 이동평균선 아래로 떨어지는 이 불길한 기술적 패턴은 종종 약세 신호로 간주된다. 아직 확정되지는 않았지만, 주식의 궤적은 최근 몇 달 동안 이전의 상승에도 불구하고 주가에 대한 압박이 증가하고 있음을 시사한다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-670051" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29072648/Screenshot-2024-11-29-at-5.05.57-PM.png" sizes="(max-width: 628px) 100vw, 628px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29072648/Screenshot-2024-11-29-at-5.05.57-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29072648/Screenshot-2024-11-29-at-5.05.57-PM-300x234.png 300w" alt="" width="628" height="490" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112924&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
읽어보세요: <a href="https://www.benzinga.com/general/biotech/24/11/42192091/biden-proposes-medicare-medicaid-access-for-popular-weight-loss-drugs">바이든, 인기 있는 체중 감량 약물에 대한 메디케어, 메디케이드 접근 제안</a>
<h2 class="wp-block-heading">VKTX 주식: 상승에서 하락으로</h2>
VKTX 주식은 올해 초 체중 감량 약물 프로그램에 대한 낙관론으로 인해 급등했다. 그러나 이러한 열정은 사라졌고, 주가는 금요일 종가 기준으로 지난 한 달 동안 26.22%, 지난 6개월 동안 14.31% 하락했다.
금요일 개장 전 주가는 54.51달러로, 20일 및 50일 단순 이동 평균선(58.72달러 및 63.04달러) 아래에서 거래되고 있어 약세 추세를 나타낸다.
한편, 바이킹의 200일 단순 이동 평균선은 62.73달러에 위치하여 데스 크로스를 가깝게 만드는 좁은 간격을 형성하고 있다. 이러한 기술적 약점은 이동평균 수렴 발산(MACD) 지표가 -3.68로 음수이며, 상대 강도 지수(RSI)가 42.11로 하락세를 나타내어 시장의 상승 모멘텀이 약화되고 있음을 나타낸다.
<h2 class="wp-block-heading">무거운 도전 과제들</h2>
분석가들은 바이킹이 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와 같은 대기업들이 지배하는 고수익 체중 감량 약물 시장에서 경쟁할 수 있는 능력에 대해 우려를 제기했다.
바이킹의 체중 감량 약물 후보들은 가능성을 보였지만, 경구용 및 주사형 버전 모두의 생산 확대는 <a href="https://www.investopedia.com/viking-therapeutics-stock-slips-after-obesity-drug-trial-results-8738997">비용이 많이 들고</a> 시간이 소요될 수 있어 단기적인 전망을 제한할 수 있다.
<h2 class="wp-block-heading">전망: 기술적 시험</h2>
다가오는 데스 크로스는 바이킹에 대한 광범위한 역풍을 반영하며, 섹터 전반의 문제로 인해 투자자 신뢰가 약화되고 있다. 그러나 바이킹이 유리한 임상 업데이트나 체중 감량 파이프라인에서의 전략적 진전을 발표하면 주식은 다시 기반을 다질 수 있다.
현재 VKTX가 중요한 기술적 붕괴의 경계에 서 있는 만큼 차트에 모든 시선이 집중되고 있다.
주가가 지지를 찾을 것인지 아니면 두려운 데스 크로스를 확정지을 것인지, 투자자들은 주의 깊게 지켜보고 있다.
주가 움직임: 바이킹 테라퓨틱스의 주식은 금요일 2.88% 하락한 52.94달러에 마감했다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42241785/us-futures-signal-gains-on-the-truncated-trading-day-will-december-witness-a-santa-claus-rally-analysts-decode">미국 주식은 11월을 높은 가격으로 마감할 가능성이 있음: 12월에 산타 랠리가 있을까요? 애널리스트들이 분석</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 6개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>AST 스페이스모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)의 주가는 회사가 <a class="ticker" href="https://www.benzinga.com//node/39958682">첫 5개의 상용 위성</a>을 성공적으로 완료하면서 47.88% 상승했다.</li>
<li>구스헤드 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>)의 주가는 긍정적인 <a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">2분기</a> 실적에 힘입어 39.86% 상승했다.</li>
<li>비아샛(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>)의 주가는 30.78% 상승했다. 회사는 새로운 보고 부문 구조를 <a class="ticker" href="https://www.benzinga.com//node/39973735">발표</a>했다.</li>
<li>바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)의 주가는 <a href="https://www.benzinga.com//node/39966690" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">VK2735의 3단계 진출</a> 발표 이후 29.86% 상승했다.</li>
<li>빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>)의 주식은 HC 웨인라이트(Wainwright)가 매수 등급으로 해당 주식에 대한 커버리지를 시작하고 <a class="ticker" href="https://www.benzinga.com/quote/BEAM/analyst-ratings">80달러의 목표 주가를</a> 발표한 후 주가는 23.93% 상승했다.</li>
<li>셀덱스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>)의 주식은 19.72% 올랐다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9c%a0%eb%8b%88%eb%b2%84%ec%85%9c-%ed%97%ac%ec%8a%a4-%eb%b0%8f-%eb%a1%9d%ed%9e%88%eb%93%9c-%eb%a7%88%ed%8b%b4%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc/" target="_blank" rel="noopener">유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일부터 7월 27일)</a></li>
</ul>
AST SpaceMobile을 통한 사진
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

수요일 미국 주요 지수는 크게 하락세로 마감했다. 다우존스 산업평균지수는 1.25% 하락한 39,853.87에, S&amp;P 500 지수는 2.3% 하락한 5,427.13에, 나스닥 지수는 3.6% 하락한 17,342.41에 마감했다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아는 6.80% 하락한 114.25달러에 마감했다. 이날 장중 최고가는 119.95달러, 최저가는 113.44달러였다. 52주 신고가는 140.76달러, 52주 신저가는 39.23달러이다. 이 회사는 다른 미국 칩 주식과 함께 수요일에 상당한 매도세를 보였다. 이는 부분적으로 테슬라와 구글의 모회사 알파벳의 <a href="https://www.benzinga.com/news/24/07/39938971/chip-stocks-nvidia-amd-and-others-see-more-selloff-on-wednesday-whats-going-on" target="_blank" rel="noopener" data-google-interstitial="false">실망스러운 2분기 실적</a> 때문이었다.
포드 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)
포드의 주식은 1.16% 하락한 13.67달러에 마감했다. 이날 주식의 최고가는 13.88달러, 최저가는 13.59달러였다. 52주 신고가는 14.85달러, 52주 신저가는 9.63달러이다. 이 자동차 제조업체는 2분기 매출이 전년 대비 <a href="https://www.benzinga.com/news/earnings/24/07/39943178/ford-q2-earnings-highlights-revenue-beat-eps-miss-transit-vans-hit-record-ev-sales-fall-37" target="_blank" rel="noopener" data-google-interstitial="false">6%</a> 증가한 478억 달러를 기록했다고 보고했으며 이는 스트리트 컨센서스 추정치인 440억 달러를 넘어섰다.
참조 자료: <a href="https://www.benzinga.com/news/24/07/39925959/kim-jong-un-rejects-donald-trumps-friendship-claims-north-korea-says-we-do-not-care-expresses-nuclea?itm_source=parsely-api" target="_blank" rel="noopener noreferrer">포드의 2분기 실적</a>
치폴레 멕시칸 그릴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)
치폴레의 주식은 51.78달러에 1.47% 하락하여 마감했다. 이날 주식의 최고가는 52.49달러, 최저가는 51.46달러였다. 52주 신고가는 69.26달러, 52주 신저가는 35.37달러이다. 이 회사는 2분기 매출이 전년 동기 대비 <a href="https://www.benzinga.com/news/earnings/24/07/39943336/chipotle-mexican-grill-q2-earnings-revenue-beat-eps-beat-comps-up-11-on-stronger-demand-trends-and-" target="_blank" rel="noopener" data-google-interstitial="false">18.2%</a> 증가한 29억 7천만 달러를 기록해 시장 예상치인 29억 4천만 달러를 넘어섰다고 보고했다.
바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)
바이킹의 주식은 2.19% 하락한 50.41달러에 마감했다. 이날 주식의 최고가는 52.18달러, 최저가는 50.27달러였다. 52주 신고가는 99.41달러, 52주 신저가는 8.28달러이다. 이 회사는 분기별 주당 손실을 <a href="https://www.benzinga.com/general/biotech/24/07/39944467/viking-therapeutics-stock-climbs-on-q2-eps-beat" target="_blank" rel="noopener" data-google-interstitial="false">20</a>센트로 보고했는데, 이는 분석가들의 합의 손실 추정치인 27센트를 25.93%나 앞선 것이다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라 주식은 12.33% 하락한 215.99달러에 마감했다. 이날 주식의 최고가는 225.99달러, 최저가는 214.71달러였다. 52주 신고가는 278.98달러, 52주 신저가는 138.8달러이다. 이 EV 거대 기업은 <a href="https://www.benzinga.com/news/24/07/39923738/tesla-reiterates-new-electric-vehicles-on-track-for-2025-but-ceo-elon-musk-refuses-to-divulge-detail" target="_blank" rel="noopener" data-google-interstitial="false">2025</a>년 상반기에 새로운 전기 자동차 생산을 시작할 계획을 다시 한번 밝혔다.
<div id="__next">
<div class="sc-hsexvf bvVSnk article-layout-wrapper">
<div class="sc-geERIb bmSvCo">
<div class="sc-dVraiA bhgqHR layout-content-container lg:px-0 mx-auto px-4 layout-container max-w-7xl">
<div class="main-content-container layout-container mx-auto">
<div class="layout-flex flex flex-col w-full items-start">
<div class="layout-main w-full overflow-hidden flex flex-grow flex-col justify-between">
<div id="node-39948172" class="sc-buPYkW iXuGvt article-content-body">
<div id="article-body" class="sc-iNCmvy cJZmSi article-content-body-only ">
<div class="sc-jEhMWw jPPXeB">

Photo by Phongphan on Shutterstock
Benzinga의 <a href="https://www.benzinga.com/markets/equities/24/07/39948172/nvidia-ford-chipotle-viking-therapeutics-tesla-why-these-5-stocks-are-on-investors-radars-today" target="_blank" rel="noopener" data-google-interstitial="false">최고 프리마켓 종목과 뉴스</a>를 통해 오늘의 거래를 준비하세요.
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener noreferrer">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)의 주가는 회사가 수요일에 2분기 재무 결과를 발표한 후 애프터마켓에서 20% 이상 급등했다. 보고서의 주요 <a href="https://www.benzinga.com/pressreleases/24/07/n39942075/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update">내용</a>은 다음과 같다.
주요 정보: 바이킹 테라퓨틱스는 분기별 손실을 주당 20센트로 보고했는데, 이는 애널리스트들의 합의된 손실 추정치인 27센트를 25.93%나 앞선 것이다.
바이킹은 2분기에 2,230만 달러의 순손실을 보고했으며, 2023년 같은 기간의 1,920만 달러 순손실과 비교된다. 2024년 6월 30일 종료된 3개월 동안 순손실 증가의 주요 원인은 앞서 언급한 연구 개발 비용 및 일반 관리비 증가 때문이며, 이는 2023년 같은 기간과 비교했을 때 증가된 이자 수익으로 부분적으로 상쇄되었다.
해당 분기 연구개발 비용은 2,380만 달러로 2023년 같은 기간의 1,390만 달러에 비해 증가했다. 바이킹은 이러한 증가가 주로 회사의 약물 후보에 대한 제조, 임상 연구, 전임상 연구, 급여 및 복리후생, 주식 기준 보상과 관련된 비용 증가로 인한 것이라고 말했다.
&#8220;2024년 상반기는 세 가지 다른 임상 시험의 성공적인 결과를 보고하고 각 프로그램의 다음 단계를 준비하기 시작하면서 회사의 파이프라인 프로그램에서 강력한 추진력을 얻었다&#8221;라고 바이킹의 CEO인 브라이언 리안(Brian Lian) 박사가 말했다.
&#8220;비만에 대한 VK2735의 2상 VENTURE 연구에서는 13주 동안 투약한 후 기초 체중에서 약 15%의 체중 감소와 유망한 안전성 및 내약성을 입증했다. FDA의 타입 C 회의에서 서면 피드백을 받은 후, 우리는 이 화합물을 3상 개발로 진행하고 있다. 현재 연말에 열릴 것으로 예상되는 2상 종료 회의를 준비 중이다&#8221;라고 리안이 덧붙였다.
VKTX 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면, 수요일 바이킹의 주식은 애프터마켓에서 23.77% 급등한 62.39달러를 기록했다.
다음 기사 읽기 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39939280/whats-going-on-with-riot-platforms-stock">라이엇 플랫폼스 주식에 무슨 일이 일어나고 있나요?</a></li>
</ul>
Csaba Nagy의 이미지 (Pixabay에서)
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Earnings

After-Hours Center

바이킹 테라퓨틱스의 주식은 예상을 뛰어넘는 2분기 EPS로 시간외 거래에서 20% 이상 급등

S&amp;P 500과 나스닥 100 지수는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39618958/us-services-sector-activity-experiences-largest-contraction-in-over-4-years-gold-ra" target="_blank" rel="noopener" data-google-interstitial="false">2020년 5월 이후 최악의 위축</a>을 겪은 6월 서비스 부문 활동이 예상보다 크게 낮아지자 투자자들이 금리 인하에 대한 기대를 높이면서 목요일 사상 최고치를 경신했다.
CME 그룹의 페드워치(FedWatch) 도구에 따르면 9월 연방준비제도(연준)의 금리 인하 가능성은 65%에서 72%로 증가했다. 트레이더들은 연말까지 50bp(베이시스 포인트) 이상의 금리 인하 가격을 책정했다. 이는 연준이 두 번의 금리 인하를 시사한다.
특히 미국 동부 시간 오후 2시에 발표될 연방공개시장위원회(FOMC) 의사록을 앞두고 위험 심리가 강했다.
iShares Semiconductor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>)가 추적하는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 칩 제조 산업은 각각 3.7%와 1.9% 상승했다.
VanEck Gold Miners ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)가 4.2% 상승하는 등 금 광산주 부문에서도 강한 상승세를 보였다. 이는 금속 가격 상승에 힘입어 올해 현재까지 가장 성과가 좋은 세션 중 하나를 기록했다.
금리 하락에 대한 기대감으로 금 가격은 1.4%, 은은 3.5%, 구리는 2.6% 상승했다.
국채 수익률은 10년물과 30년물 수익률이 모두 7bp 하락하는 등 급격하게 약세를 보였다. iShares 20+ Year Treasury Bond ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>)는 1.1% 상승해 6월 13일 이후 가장 높은 상승률을 기록했다.
그러나 크립토 시장은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)이 60,450달러로 2.7% 하락했다.
<h3 class="wp-block-heading">주요 미국 지수와 ETF의 수요일 성과</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>주요 지수</td>
<td>가격</td>
<td>1일 변동률</td>
</tr>
<tr>
<td>나스닥 100</td>
<td>20,168.73</td>
<td>0.8%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,531.06</td>
<td>0.4%</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>202.16</td>
<td>0.1 %</td>
</tr>
<tr>
<td>다우 존스</td>
<td>39,273.72</td>
<td>-0.1%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">동부시간 12:28 p.m. 기준</figcaption></figure>
<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent070324&amp;t=be2bearmibe3na1">Benzinga Pro</a>의 데이터에 따르면:
<ul>
<li>SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 0.3% 상승한 550.85달러로 마감했다.</li>
<li>SPDR 다우존스 산업평균 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)가 0.2% 하락한 392.45달러로 마감했다.</li>
<li>기술주 중심의 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 0.8% 상승한 490.70달러를 기록했다.</li>
<li>Technology Discretionary Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)는 1.3% 상승했으며, 이에 비해 Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)는 1% 하락했다.</li>
</ul>
<h3 class="wp-block-heading">수요일 주식 변동:</h3>
<ul>
<li>체중 감량 약물 대기업인 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)는 매사추세츠 아이 앤드 이어(Massachusetts Eye and Ear)에서 실시한 연구에서 오젬픽(Ozempic)과 위고비(Wegovy)가 실명의 눈 질환 위험이 더 높은 것으로 나타난 후 각각 1.9%와 4% 하락했다. 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)과 바이킹 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)도 각각 1.9%, 2.2% 하락했다.</li>
<li>테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주가는 화요일부터 전기 자동차 제조업체의 분기별 납품 실적이 예상보다 좋은 이후 5.5% 상승하는 등 상승 모멘텀을 이어갔다.</li>
<li>기타 전기차 관련 주식도 상승세를 보였는데, 루시드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)가 8%, 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>)가 15% 상승했다.</li>
<li>파라마운트 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)은 스카이댄스(Skydance)가 파라마운트의 지배 회사인 내셔널 어뮤즈먼트(National Amusements) 인수 거래에 다시 관심을 갖고 있다는 월스트리트 저널의 소문에 따라 7% 이상 급등했다.</li>
<li>콘스텔레이션 브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)는 지난 분기 매출이 예상보다 낮은 가운데, 4.4% 하락해 2023년 10월 이후 최악의 세션을 기록했다.</li>
</ul>

Comments

Viking Therapeutics

뉴스

에 대한 최신 뉴스 Viking Therapeutics (NASDAQ:VKTX) 주식

토요일, 11월 30, 2024

월요일, 7월 29, 2024

목요일, 7월 25, 2024

목요일, 7월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌